• Disease
  • Venous
  • Venous Thromboembolism
  • Jack Hirsh

    Prominent publications by Jack Hirsh

    KOL Index score: 27246

    This article discusses the management of venous thromboembolism (VTE) and thrombophilia, as well as the use of antithrombotic agents, during pregnancy and is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that benefits do, or do not, outweigh risks, burden, and costs. Grade 2 recommendations are weaker and imply that the magnitude of the benefits and risks, burden, and costs are ...

    Also Ranks for: Antithrombotic Therapy |  venous thromboembolism |  ufh pregnancy |  8th edition |  pregnant women
    KOL Index score: 17340

    Propagation of venous thrombi or rethrombosis after coronary thrombolytic therapy can occur despite heparin administration. To explore potential mechanisms, we set out to determine whether clot-bound thrombin is relatively protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. Using plasma fibrinopeptide A (FPA) levels as an index of thrombin activity, we compared the ability of thrombin inhibitors to block FPA ...

    Also Ranks for: Bound Thrombin |  inhibition heparin |  independent inhibitors |  fibrin fibrinopeptide |  citrated plasma
    KOL Index score: 16373

    BACKGROUND: Nonspecific binding to plasma proteins decreases the anti-factor Xa (anti-Xa) activity of unfractionated heparin (UFH) but not that of low-molecular-weight heparin (LMWH). However, plasma proteins could influence the anti-thrombin (anti-IIa) activity of LMWH. To explore this possibility, we compared the effects of plasma proteins on the anti-IIa activities of UFH and LMWH. We also examined their effects on the anti-IIa activity of dermatan sulfate (DS) because, like UFH, DS ...

    Also Ranks for: Plasma Proteins |  dermatan sulfate |  unfractionated heparin |  ufh lmwh |  nonspecific binding
    KOL Index score: 16213

    This chapter about the use of antithrombotic agents during pregnancy is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations ...

    Also Ranks for: Lmwh Pregnancy |  thrombolytic therapy |  grade 1c |  antithrombotic agents |  vte women
    KOL Index score: 15495

    This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring of anticoagulation intensity, the clinical applications of VKA therapy, and the optimal therapeutic range of VKAs, and provides specific management recommendations. Grade 1 ...

    Also Ranks for: Management Patients |  grade 2c |  vitamin antagonists |  thrombolytic therapy |  low risk thromboembolism
    KOL Index score: 15464

    Three mechanisms by which sulfated polysaccharides act as anticoagulants and possibly as antithrombotic agents have been described. These are the two heparin cofactor-dependent mechanisms involving the catalysis of the inhibition of various proteases of coagulation by either antithrombin III or heparin cofactor II. The third is a heparin cofactor-independent mechanism involving the inhibition of formation of prothrombinase and tenase complexes. Four sulfated polysaccharides previously ...

    Also Ranks for: Thrombin Activity |  sulfated polysaccharides |  activation factor |  catalysis inhibition |  iii heparin
    KOL Index score: 15153

    BACKGROUND: The Hip and Knee Registry is an observational database comprising data on practices of US orthopedic surgeons during 1996 to 2001. We examined trends in the use of prophylaxis for venous thromboembolism (VTE) among patients who underwent primary total hip arthroplasty (THA) or total knee arthroplasty (TKA).

    METHODS: Data on 9,327 THA and 13,846 TKA patients were submitted between 1996 and 2001 by 464 orthopedic surgeons from 319 hospitals in 42 of the United States.

    RESULTS: ...

    Also Ranks for: Knee Arthroplasty |  venous thromboembolism |  tha tka |  united states |  total hip
    KOL Index score: 15045

    Adjusted doses of oral warfarin sodium or fixed doses of subcutaneous low-molecular-weight heparin (LMWH) are the standard approaches for preventing venous thromboembolism following major orthopedic surgery of the legs. In recent years, new anticoagulants have been compared with either LMWH or warfarin. The optimal timing for the first dose of LMWH prophylaxis and of the new anticoagulants is controversial. Recent clinical trials of LMWH and of newer anticoagulants have provided new ...

    Also Ranks for: Major Orthopedic Surgery |  venous thromboembolism |  anticoagulant prophylaxis |  optimal timing |  6 12
    KOL Index score: 14728

    Heparin catalyses the inhibition of two key enzymes of blood coagulation, namely Factor Xa and thrombin, by enhancing the antiproteinase activities of plasma antithrombin III and heparin cofactor II. In addition, heparin can directly inhibit the activation of Factor X and prothrombin. The contributions of each of these effects to the anticoagulant activity of heparin have not been delineated. We therefore performed experiments to assess how each of these effects of heparin contributes to ...

    Also Ranks for: Inhibition Thrombin |  pentosan polysulphate |  plasma heparin |  activation factor |  anticoagulant activity


    Jack Hirsh: Influence Statistics

    Sample of concepts for which Jack Hirsh is among the top experts in the world.
    Concept World rank
    venograms consecutive patients #1
    higher doses sh #1
    acutephase reaction levels #1
    disruption procedure #1
    inr reporting #1
    heparin therapy pregnancy #1
    heparin 20 patients #1
    unstable heparin #1
    incidence wound hematoma #1
    blind endpoint assessment #1
    heparin clearance differences #1
    hospital 253 patients #1
    cardiovascular mortality aspirin #1
    clotbound thrombin inactivation #1
    125ifibrinogen leg scanning #1
    radiation exposure fetus #1
    streptokinase resolution #1
    ufh ufh antithrombin #1
    activity clotbound enzyme #1
    women catheter #1
    dermatan sulphate pentosan #1
    salicylate dipyridamole treatment #1
    scan perfusion defects #1
    treatment 14 episodes #1
    major bleeding level #1
    verylowdose warfarin prevention #1
    protamine sulphate inhibition #1
    ultrasound result dvt #1
    extended ardeparin patients #1
    patients recurrent thrombosis #1
    thromboembolism postoperatively #1
    contrast hirugen #1
    venous thromboembolism recurrence #1
    14 episodes thrombosis #1
    venous bloodflow leg #1
    plasma dpheproargch2cl #1
    10mg loading dose #1
    plasminogen activators patients #1
    suspected venous thrombosis #1
    ppack sulfated polysaccharides #1
    vte bolus #1
    concentrations sulfated polysaccharides #1
    prevention systemic embolism #1
    patients 12week #1
    extension established thrombosis #1
    heparindependent igg antibodies #1
    lysis venous thrombi #1
    fluidphase thrombin activity #1
    response maintenance dose #1

    Key People For Venous Thromboembolism

    Top KOLs in the world
    John A Heit
    venous thromboembolism pulmonary embolism alcohol dependence
    Harry Roger Büller
    pulmonary embolism venous thrombosis major bleeding
    Paolo Prandoni
    venous thromboembolism pulmonary embolism vein thrombosis
    Samuel Zachary Goldhaber
    pulmonary embolism atrial fibrillation major bleeding
    Martin Hendrik Prins
    venous thromboembolism pulmonary embolism intermittent claudication
    Giancarlo Agnelli
    venous thromboembolism pulmonary embolism atrial fibrillation

    Jack Hirsh:Expert Impact

    Concepts for whichJack Hirshhas direct influence:Venous thromboembolism,  Pulmonary embolism,  Venous thrombosis,  Unfractionated heparin,  Impedance plethysmography,  Deep vein thrombosis,  Weight heparin,  Molecular weight.

    Jack Hirsh:KOL impact

    Concepts related to the work of other authors for whichfor which Jack Hirsh has influence:Venous thromboembolism,  Pulmonary embolism,  Atrial fibrillation,  Deep vein thrombosis,  Unfractionated heparin,  Platelet aggregation,  Oral anticoagulants.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada | Department of Medicine, McMaster University, Hamilton, Canada (J.H., N.C.C.). | Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada (J